Journal Article Summary
The article investigates the use of cost-benefit analysis (CBA) to compare pharmaceutical treatments for menorrhagia, a condition characterized by heavy menstrual bleeding that can significantly impact a woman's quality of life. Traditional methods of evaluating treatment effectiveness often focus solely on health-related outcomes, which may not fully capture the broader implications of menorrhagia on women's lives. By exploring a different approach—willingness to pay (WTP)—the study aims to provide a more comprehensive understanding of the value women place on different treatment options.
In this study, researchers conducted a cost-benefit analysis over a 24-month period involving 99 women from a UK primary care setting. Participants were asked to express how much they would be willing to pay for two treatments: the levonorgestrel-releasing intrauterine system (LNG-IUS) and oral medication. The findings indicated that oral treatment was more cost-beneficial, costing £107 less than LNG-IUS while providing greater overall benefits, resulting in a positive net present value (NPV) of £45 for oral treatment compared to a negative NPV of £−68 for LNG-IUS.
Despite its strengths, the study has limitations, including a convenience sample that may not fully represent the broader population of women with menorrhagia. Additionally, the analysis focused solely on healthcare costs, excluding societal costs that could provide a more complete picture of the economic impact. Patients should discuss these findings with their healthcare professionals, particularly regarding treatment options for menorrhagia, as the study suggests oral treatment may be a more effective first-line option compared to LNG-IUS.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Sanghera Sabina, Frew Emma, Gupta Janesh Kumar, Kai Joe, Roberts Tracy Elizabeth. Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia. Pharmacoeconomics 2015. DOI: 10.1007/s40273-015-0280-0. PMID: 25911537. PMCID: PMC4559088.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
